A 52-week mulicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and inmonogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascuar age-related macular degeneration.
01/08/2023
INVESTIGADOR:
Dr. Álvaro Fernández-Vega Sanz
FINALIZADO
A 52-week mulicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and inmonogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascuar age-related macular degeneration.